Bauer Eugene 4

What Happened
Eugene Bauer, Chief Medical Officer and a director of Evommune, Inc. (EVMN), was granted 51,117 derivative shares (an option/award) on April 16, 2026. The Form 4 reports an acquisition price of $0.00 (derivative instrument), so no cash was paid at grant; this is a compensatory award rather than an open-market purchase or sale.

Key Details

• Transaction type: Award/Grant (Form 4 code A), derivative instrument reported.
• Date of transaction: 2026-04-16; filing date: 2026-04-17 (timely).
• Shares involved: 51,117 shares; price reported: $0.00; total reported value: $0.
• Shares owned after transaction: Not specified in the provided filing.
• Vesting: Per footnote — 1/4 vests on the first anniversary of the grant, remainder vests in 36 equal monthly installments thereafter, subject to continued service.
• No indication of immediate sale, tax-withholding, or a 10b5-1 plan in the provided filing.

Context
This appears to be a standard equity compensation award to align management incentives and retain the executive; such grants do not represent an open-market buy or sell. Because vesting is time-based, the economic benefit to the insider depends on continued service and any future exercise or sale of underlying shares. For retail investors, awards are informative about compensation and retention but are not a direct signal of immediate buying or selling in the market.